Triple therapy before surgery for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy, radiation, and immunotherapy (pembrolizumab) before surgery for pancreatic cancer that can be removed. It aims to see if this triple therapy helps shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that is confirmed by a biopsy.
- Your cancer must be able to be removed by surgery, either right away or after some shrinkage.
- You must be at least 18 years old and in good enough health to walk and take care of yourself (ECOG 0-1).
- You cannot have had prior immunotherapy, chemotherapy, or radiation for this cancer.
- You must not have an active autoimmune disease or a history of severe lung inflammation.
- You must be willing to use birth control during and for 18 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
Hear when a new Borderline Resectable Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.